Evidence for a role of T-helper type 2 cytokines in the acquisition of human immunodeficiency virus syncytium-inducing phenotype

European Journal of Clinical Investigation

Volumn 28, Issue 11, 1998, Pages 930-936

  Torres, Y ^a   Medrano, F J ^a   Rey, C ^a   Calderon E J ^a   Sanchez Quijano A ^a   Lissen, E ^a   Leal, M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Cytokines; Human immunodeficiency virus type 1; Syncytium inducing phenotype; T helper response

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BLOOD LEVEL; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PHENOTYPE; PRIORITY JOURNAL; SYNCYTIUM; VIRUS TYPING;

CASE-CONTROL STUDIES; CYTOKINES; CYTOPATHOGENIC EFFECT, VIRAL; GIANT CELLS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; PHENOTYPE; TH2 CELLS;

EID: 0031775721     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00368.x     Document Type: Article

References (36)

1. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993; 262: 1011-7.
2. Tersmette M, deGoede REY, Al BJM, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988; 62: 2026-32.
3. Cheng-Mayer C, Seto D, Tateno M, Levy JA. Biologic features of HIV-1 that correlate with virulence in the host. Science 1988; 240: 80-2.
4. Tersmette M, Gruters RA, DeWolf F, et al. Evidence for a role of virulent human inmunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 1989; 63: 2118-25.
5. Tersmette M, Lange JMA, de Goede REY, et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989; 1: 983-5.
6. Schuitemaker H, Koot M, Koostra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 1992; 66: 1354-60.
7. Koot M, Keet IPM, Vos AHV, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118: 681-8.
8. Koot M, Vos AHV, Keet RPM, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992; 6: 49-54.
9. Schellekens PTA, Tersmette M, Roos M, et al. Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS 1992; 6: 665-9.
10. Boucher CAB, Lange JMA, Miedema FF, et al. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992; 6: 1259-64.
11. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169: 968-74.
12. Karlsson A, Parsmyr K, Sandström E, Fenjo EM, Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994; 32: 364-70.
13. Clerici M, Shearer GM. An Occam's razor approach to the immunopathogenesis of HIV infection. AIDS 1995; 9 (Suppl. a): s33-s40.
14. Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14: 107-10.
15. Clerici M, Hakim FT, Venzon DJ, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993; 91: 759-65.
16. Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 1994; 265: 244-8.
17. Graziosi C, Pantaleo G, Gantt KR, et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 1994; 265: 248-52.
18. Tersmette M, Miedema F. Interactions between HIV and the host immune system in the pathogenesis of AIDS. AIDS 1990; 4: S57-66.
19. Miedema F, Tersmette M, Vanlier RAW. AIDS pathogenesis -A dynamic interaction between HIV and the immune system. Immunol Today 1990; 11: 293-7.
20. Bozzette SA, McCutchan JA, Spector SA, Wright B, Richman DDA. Cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 1993; 168: 1374-9.
21. Kozal MJ, Ramachandran RV, Shafer RW. Prevalence of HIV-1 syncytium-inducing phenotype. Ann Intern Med 1994; 120: 811.
22. Leal M, Torres Y, Medrano FJ, Calderón EJ, Rey C, Lissen E. Does early zidovudine treatment prevents the emergence of syncitium-inducing human immunodeficiency virus? J Infect Dis 1994; 170: 1041.
23. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332: 201-8.
24. Torres Y, Medrano FJ, Rey C, et al. Cytokine network and HIV syncytium-inducing phenotype shift. AIDS 1996; 10: 1053-5.
25. Luque F, Caruz A, Pineda JA, Torres Y, Larder B, Leal M. Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients. J Infect Dis 1994; 169: 267-73.
26. Leal M, Torres Y, Medrano FJ, et al. HIV-1 viremia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: a case control study. Eur J Clin Invest 1996; 26: 923-8.
27. Torres Y, Leal M, Rey C, Medrano FJ, Sanchez-Quijano A, Lissen E. Acquisition of Syncytium-inducing HIV-1 strains during therapy with zidovudine alone or combined with alpha interferon or didanosine. Eur J Clin M Infect Dis 1996; 15: 324-7.
28. Cooper DA, Gatell JM, Kroon S, et al. European-Australian collaborative group: Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329: 297-303.
29. 6/1, results of the Zidon trial. AIDS 1995; 9: 1025-35.
30. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41 (RR-17): 1-19.
31. Gearing AJH, Cartwright JE, Wadhwa M. Biological and immunological assays for cytokines. In: Thomson AW, ed. The Cytokine Handbook. London: Academic Press Limited 1994; 507-24.
32. Weiss RA. How does HIV cause AIDS? Science 1993; 260: 1273-8.
33. Cornelissen M, Mulder-Kampinga G, Veenstra J, et al. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/ SI phenotypically mixed human immunodeficiency virus population. J Virol 1995; 69: 1810-8.
34. Valentin A, Albert J, Fenyo EM, Asjo B. Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates. J Virol 1994; 68: 6684-9.
35. de Jong JJ, de Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1, V3 domain to support the syncytium-inducing (SI) phenotype: analysis by single amino acid substitution. J Virol 1992; 66: 6777-80.
36. Fauci AS. Host factor and the pathogenesis of HIV-induced disease. Nature 1996; 384: 529-34.